Fentanyl for Treatment Pain Caused by Radiotherapy
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to assess the clinical utility and safety of Fentanyl for pain treatment caused by radiotherapy. Fentanyl is a synthetic pure opioid agonist with a selective activity on µ receptors.
Full description
The study is a phase IV, open label, single arm study. The purpose of this study is to assess the clinical utility and safety of fentanyl transdermal therapeutic system (patch) for treatment of pain caused by radiotherapy. The patients increase or even decrease the amount of study medication in order to achieve pain relief, 48 to 72 hours or 3 days are required after the first patch application. The study medication will be used for 4 weeks. VAS (visual analog scale), BPI Q9 (quality of life) and global assessment have been used to assess the effectiveness. VAS will be assessed every week. BPI Q9 will be assessed at week 1 and week 4. Global assessment will be assessed at week 4. The safety of the study drug will be evaluated using adverse event (AE) report.
The investigator will assess the pain intensity of patients and increase or even decrease Fentanyl dosage every week. Fentanyl will be started on 25 or 50 ug per hr depending on investigator's judgement. Fentanyl will be administered for 4 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients have the history of head and neck tumor
- Patients who are proceeding radiotherapy
- Patients who are administered weak opioids and pain score (Visual analog scale) of 4
Exclusion criteria
- Patients who have been administered Fentanyl for pain treatment within 2 weeks before the study
- Patients who will have surgery within 1 month
- Known presence of distant metastasis
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal